AzTrials
AzTrials

Myocardial DysfunctionNCT04060381

Myocardial Deformation Before and After Birth

An observational study of Myocardial Dysfunction and Newborn Morbidity, run by Haukeland University Hospital at 1 site in Norway.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Knowledge on the changes in myocardial function in the last weeks before birth and during the first year of life is limited. Through fetal and post-natal echocardiography we intend to describe these changes using myocardial tissue recognition techniques (Speckle tracking echocardiography and Tissue Doppler… Read more about this study

Who is it for?
Ages Up to 3 weeks
What is being tested?
Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
How many people
300 participants
Where
1 siteNorway
Study dates
4 Apr 2017to Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 3 weeks
  • All sexes
  • No healthy volunteers
  • Child

Study population: Either recruited during pregnancies or as newborns

Who may be able to join

  • Normal pregnancies
  • Newborns in need of blood transfusion
  • Newborns in need of medical closure of the arterial duct
  • Maternal obesity

Who cannot join

  • Abnormal pregnancies except maternal obesity
  • Congenital heart defects
  • Other malformation syndromes

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Haukeland University Hospital

    Bergen, 5020

Other trials in Norway

About this study

Official title: Myocardial Deformation Before and After Birth, and Under Altered Preload, Afterload and Heart Rate in New-borns

Knowledge on the changes in myocardial function in the last weeks before birth and during the first year of life is limited. Through fetal and post-natal echocardiography we intend to describe these changes using myocardial tissue recognition techniques (Speckle tracking echocardiography and Tissue Doppler echocardiography) in healthy neonates, born to term of healthy women after uncomplicated pregnancies. We will compare the findings in this cohort to a cohort of neonates born to term of women with severe pre-pregnancy obesity.

Sick neonates in intensive care units with various cardiac and non-cardiac conditions are often exposed to treatment that may affect both their cardiac function and important echo-variables per se. Using echocardiography, we will examine these changes in neonates treated with blood transfusion, catecholamines and in those treated with Ibuprofen due to a haemodynamic significant arterial duct.

Read the detailed description

Before, during and after birth major changes take place in the cardiovascular system. The last weeks prior to birth there is an oxidative stress and after birth, there is normally a large step up in blood oxygen tension when the lungs take over oxidation of the blood. Simultaneously there are changes in the vascular resistance in both the pulmonary- and systemic part of the circulation and ductus venous, the arterial duct, and foramen ovale close. Combined these will significantly alter the physical conditions under which the myocardium is supposed to work.

This project will have five arms, all based on measurements of myocardial function and coronary perfusion by speckle tracking echocardiography (STE) in the last trimester of the pregnancy and in newborns with different gestational age and in sick newborns where myocardial function is affected by medical treatment or is an important part of the clinical situation.

  1. Obtaining normal values for strain during the last trimester of the pregnancy and the first days after birth in child born to term. Hypothesis: After birth, there will be higher STE values in the left ventricle than before birth. This will increase further the first days post-partum in parallel with an altered hemodynamic situation and oxygen demand of the infant. The STE changes will take place at the same time, as there is an increased Doppler velocity in the aorta, the pulmonary artery and the coronary arteries Mothers (N= 150) will be recruited when they are coming to a routine fetal ultrasound scan. It will be made an echo-examination once per week from week 37 until birth. After birth the degree of placental transfusion (late cord clamping or not) will be noticed. Ventricular size, Doppler velocities in the ascending aorta and pulmonary artery, STE and coronary flow during the first three days of life and one year of age will be assessed
  2. Evaluate the effect of maternal obesity on cardiac function in newborns up to one year of age. Hypothesis: Maternal sever obesity will result in reduced cardiac function in their neonates. However, cardiac function will normalize within the first year of life. A reduction in afterload will reduce strain measured by STE and coronary. Mothers (N=75) with sever obesity will be recruited from the outpatient clinic for obese women. First day after birth, the newborn will have a comprehensive echocardiographic examination within the first few hours, then the two following days, at the day equivalent to gestational age 42+0 weeks and finally at 1 year of age. Cardiac morphology, ventricular sizes and Doppler velocities in the ascending aorta and pulmonary artery as well as a strain measured by STE for both ventricles will be assessed. Fetal malformations or diseases will result in exclusion from the study.
  3. Measuring deformation when preload is increased by intravenous fluid treatment and blood transfusion Hypothesis: Increased preload in the form of saline infusion or blood transfusion will result in a temporary increase of STE and coronary blood flow. Newborns (N=25 blood transfusion and 25 NaCl-infusion) who need infusion of sodium chloride (NaCl 9mg) / ml or transfusion of packed red blood cellssuspended in 100 mL of saline- adenine-glucose-mannitol (SAGMAN) will be recruited. To obtain rehydration or optimization of intravascular volume it is common to provide NaCl 9 mg/ml, 10-20 ml/kg in 10-120 minutes. Blood transfusion is used in severe anemia and hemolytic diseases. The regular blood transfusion dose is SAGMAN packed red blood cells10-15ml/ kg body weight over 2-3 hours. Children requiring exchange transfusion, with heart failure or congenital heart defects will be excluded.
  4. Measuring deformation when afterload and heart rate are increased during infusion of catecholamines. Hypothesis: Dopamine, epinephrine and/ or nor-epinephrine will increase heart rate and blood pressure and due to this increase the strain measured by STE, coronary blood flow, and Doppler velocity in the aorta pulmonary artery. Newborns (N=25) who need dopamine (2.5 to 15 ug/kg /min iv.) and or epinephrine / nor-epinephrine to maintain an adequate blood pressure will be recruited. Only children where an echo-exam before starting treatment is possible will be recruited. If the treatment does not achieve a rise in the blood pressure above the 2.5 percentile for gestational age, the baby will be excluded.
  5. Measuring deformation when afterload (volume) is reduced following pharmacological closure of a patent ductus arteriosus.

Hypothesis: A reduction in afterload will reduce strain measured by STE and coronary.

Patients (N=25) with a suspected patent ductus arteriosus (PDA) are always referred to echocardiography before starting treatment with Indomethacin and after the treatment has stopped. Present clinical procedures for closure of the ductus will be followed, . Time of echocardiography will be standardized to just before and at least 12 hours after the last dose of Ibuprofen has been provided (t½ ≈ 2.5-11 hrs.).

Being tested
Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
Keywords
Spackle tracking echocardiography, Tissue doppler, Neonates, Infants, Maternal obesity
Medical subject headings
Pregnancy in Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamineDrug

    Also called Volume treatment, Blood pressure elevation

    Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit

Study groups in NCT04060381
Study groupRoleWhat they receive
Fetuses of normal weight womenFetuses of normal pregnancies of normal weight mothers are included from gestational week 37
Fetuses of severely obese womenFetuses of normal pregnancies of severly obese mothers are included from gestational week 37
New-borns in need of blood transfusionNeonates mainly receive blood due to blood loss, often because of repeated blood sampling
Receives: Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
New-borns in need for closure of the arterial ductNeonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
Receives: Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in myocardial function

    Per cent change in longitudinal global strain

    Measured: Maximum 1 year and 5 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2019
  2. Study start4 Apr 2017
  3. Primary completionDec 2023 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04060381
Sponsor's protocol ID
2015/1918
Status last verified
Mar 2023
First submitted
15 Aug 2019
Last updated
6 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Eventually strain data.

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Dysfunction and Newborn Morbidity, run by Haukeland University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in myocardial function (time frame: Maximum 1 year and 5 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in